Biocon Appoints Shreehas Tambe as CEO & Managing Director
Filing Summary
Biocon Limited has appointed Shreehas Tambe as its new Chief Executive Officer and Managing Director, effective April 1, 2026. This appointment follows the approval of the Nomination & Remuneration Committee and the Board of Directors. The leadership change coincides with the integration of Biocon Biologics Limited as a wholly owned subsidiary, streamlining the corporate structure. Kedar Upadhye has been named Chief Financial Officer. The company aims to enhance its global operations in biosimilars and generics. The transition supports Biocon’s focus on diabetes, obesity, oncology, and immunology.
Biocon Limited has announced the appointment of Shreehas Tambe as the Chief Executive Officer and Managing Director, effective April 1, 2026. This decision was approved by the Nomination & Remuneration Committee and the Board of Directors. The appointment marks a significant leadership transition as Biocon integrates Biocon Biologics Limited as a wholly owned subsidiary, creating a unified corporate structure. Kedar Upadhye has also been appointed as the Chief Financial Officer of Biocon Limited.
The integration of Biocon Biologics Limited is part of a strategic move to simplify the corporate structure and enhance operational efficiency. The unified entity will focus on expanding its presence in the global biosimilars and generics markets. The company aims to leverage its combined platform to operate at scale, addressing key therapy areas such as diabetes, obesity, oncology, and immunology. The transition is expected to streamline operations and improve the company’s ability to compete in international markets.
The operational scope of the newly integrated Biocon includes a diversified portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies. The company plans to focus on advancing its research and development pipeline, which includes over 20 biosimilar assets. Biocon’s integrated lab-to-patient model combines research, development, manufacturing, and commercial capabilities to ensure a reliable supply of medicines across more than 120 countries.
The leadership transition will be effective from April 1, 2026. Shreehas Tambe, who has been with Biocon for nearly three decades, will lead the combined business as the first CEO of the integrated entity. His previous roles include CEO and Managing Director of Biocon Biologics, where he played a key role in the acquisition and integration of Viatris’ biosimilars business. The transition aims to consolidate Biocon’s business operations and accelerate sustainable growth.
Shreehas Tambe will be responsible for strengthening Biocon’s position as a global biopharma leader. His leadership will focus on advancing a differentiated portfolio of biosimilars, insulins, generics, and peptides. Kedar Upadhye, as the new Chief Financial Officer, will oversee the financial operations of the company. The leadership team will work towards enhancing Biocon’s global footprint and addressing pressing healthcare needs.
The integration of Biocon Biologics Limited as a wholly owned subsidiary is a strategic move to create a globally scaled biopharma enterprise. The company aims to address high unmet needs in chronic and non-communicable diseases through its biosimilars and generics offerings. Biocon has commercialized 12 biosimilar products and over 30 generic formulations globally. The company is committed to sustainable growth, as evidenced by its inclusion in the S&P Global Sustainability Yearbook 2026.
Biocon Limited is a global biopharmaceutical company focused on providing affordable, life-changing medicines. The company addresses healthcare challenges across chronic and non-communicable diseases, offering biosimilars and generics at scale. Biocon operates in over 120 countries, supported by multiple manufacturing and R&D sites, and a workforce of over 9,500 employees. The company is committed to advancing innovation and expanding its global presence.